Sign in

    Karin Johnson

    Research Analyst at Goldman Sachs

    There is no publicly available professional profile for Karin Johnson as an analyst at Goldman Sachs, and no credible information confirming this individual's employment, job title, coverage, performance metrics, career history, or credentials at the firm. Extensive searches revealed no LinkedIn profile or verifiable mention of a Karin Johnson in an analyst or equity research capacity at Goldman Sachs, nor on reputable analyst ranking platforms. Without such data, a comprehensive career summary cannot be provided.

    Karin Johnson's questions to Altimmune (ALT) leadership

    Karin Johnson's questions to Altimmune (ALT) leadership • Q3 2024

    Question

    Omar, on behalf of Karin Johnson from Goldman Sachs, inquired about the selection criteria for the three new indications and the anticipated size of the first Phase II trial scheduled to begin in the first half of 2025.

    Answer

    CMO Dr. Scott Harris explained that the indications were chosen based on targets in patients with obesity that would specifically benefit from glucagon's effects. He emphasized these will be Phase II proof-of-concept studies, not Phase I, and that further details on the indications and trial sizes will be provided after regulatory discussions are completed.

    Ask Fintool Equity Research AI